09:47 AM EST - Acerus Pharmaceuticals Corporation : Today announced the completion of the NATESTO® U.S. transition from an affiliate of Endo International plc back to Acerus, and subsequently to Aytu BioScience, Inc. Aytu will now assume responsibility for the U.S. commercialization of NATESTO®, the first and only FDA-approved testosterone nasal gel indicated for replacement therapy in adult males diagnosed with hypogonadism. Acerus Pharmaceuticals Corporation
shares T.ASP are trading up $0.005 at $0.11.
